Translational Neuropsychopharmacology

ISBN-13: 9783319816302 / Angielski / Miękka / 2018 / 498 str.

Trevor W. Robbins; Barbara J. Sahakian

Recenzje

"This book examines the 'translational gap' between animal models of neuropsychiatric disease and human studies. ... The intended audience is scientists working on problems related to neuropsychopharmacology. ... This is an important addition to the literature on translational neurosciences. It is an important contribution to understanding both the current state of this field and its possible future directions." (Eric Gausche, Doody's Book Reviews, November, 2016)

Spis treści

Translational mouse models of autism; Advancing towards pharmacological therapeutics.- Translatable and back-translatable measurement of impulsivity and compulsivity; convergent and divergent processes.- Translational models of gambling-related decision-making.- Translational research on nicotine dependence.- The need for treatment-responsive translatable biomarkers in alcoholism research.- On the road to translation for PTSD treatment: theoretical and practical considerations of the use of human models of conditioned fear for drug development.- Translational approaches targeting reconsolidation.- Translational assessment of reward and motivational deficits in psychiatric disorders.-                Affective biases in humans and animals. Robinson.- Locomotor profiling from the rodents to the clinic and back again.- Animal models of sensori-motor gating in schizophrenia: Are they still relevant?.- Attention and the cholinergic system: relevance to schizophrenia.- Attentional-set-shifting across species.- Relating Translational Neuroimaging and Amperometric Endpoints: Utility for Neuropsychiatric Drug Discovery.- Cognitive translation using the rodent touchscreen test approach.- The Paired Associates Learning (PAL) Test:  30 years of CANTAB Translational Neuroscience From Laboratory to Bedside in Dementia Research.- Translational approaches to experimental medicine.

Blurb

This book covers wide areas of animal and human psychopharmacology with clinical utility in the treatment of psychiatric and neurological (e.g Alzheimer's disease) disorders. The main theme is to develop a new paradigm for drug discovery that questions the claim that animal models or assays fail adequately to predict Phase 3 clinical trials. A new paradigm is advocated that stresses the importance of intermediate staging points between these extremes that depend on suitable translation of findings from animal studies to Phase 1 or Phase 2 studies utilising experimental medicine.